press releases

LYSOGENE releases the results from June 26, 2020 ordinary annual and extraordinary general meeting
LYSOGENE releases the results from June 26, 2020 ordinary annual and extraordinary general meeting 150 150 Lysogene

Shareholders approved all proposed resolutions Paris, France — 26 June 2020 — Lysogene (FR0013233475-LYS) held…

Lysogene announces important updates on AAVance phase 2/3 clinical trial with LYS-SAF302 in MPS IIIA
Lysogene announces important updates on AAVance phase 2/3 clinical trial with LYS-SAF302 in MPS IIIA 150 150 Lysogene

Paris, France — 05 June 2020 at 08:00am CEST— Lysogene (FR0013233475 – LYS), a Phase…

LYSOGENE Annual Ordinary and Extraordinary General Meeting of 26 June 2020 Availability of the Preparatory Documents
LYSOGENE Annual Ordinary and Extraordinary General Meeting of 26 June 2020 Availability of the Preparatory Documents 150 150 Lysogene

Paris, France — 20 May 2020 at 06:00pm CEST— Lysogene (FR0013233475 – LYS), a Phase…

Lysogene Announces Presentations at Upcoming Meetings:
Lysogene Announces Presentations at Upcoming Meetings: 150 150 Lysogene

2020 American Society of Gene & Cell Therapy Annual (ASGCT) virtual Meeting European Forum for…

Kepler Cheuvreux initiates coverage of Lysogene
Kepler Cheuvreux initiates coverage of Lysogene 150 150 Lysogene

Paris, France — 13 May 2020 at 06:00pm CEST — Lysogene (FR0013233475 – LYS), a…

Lysogene Announces Filing of 2019 Universal Registration Document
Lysogene Announces Filing of 2019 Universal Registration Document 150 150 Lysogene

PARIS, France – 30 April 2020 – Lysogene (FR0013233475 – LYS), a Phase 3 gene…

Lysogene Reports its Cash Position as of 31 March 2020
Lysogene Reports its Cash Position as of 31 March 2020 150 150 Lysogene

Cash and cash equivalent of €29.9 million1 as of 31 March 2020 PARIS, France –…

Lysogene Reports Full Year 2019 Financial Results and Provides Operational Update
Lysogene Reports Full Year 2019 Financial Results and Provides Operational Update 150 150 Lysogene

Cash position of 26.5 M€ as of 31 December 2019 19 patients treated out of…

Lysogene announces the date of its 2020 General shareholders’ meeting and amends its financial calendar
Lysogene announces the date of its 2020 General shareholders’ meeting and amends its financial calendar 150 150 Lysogene

PARIS (France), 16 March 2020 – Lysogene (FR0013233475 – LYS) today announced the amendment of…

Lysogene completes €7.7 million capital increase in a placement led by leading healthcare investor OrbiMed and Lysogene shareholder and partner Sarepta
Lysogene completes €7.7 million capital increase in a placement led by leading healthcare investor OrbiMed and Lysogene shareholder and partner Sarepta 150 150 Lysogene

PARIS, France – 12 March 2020 – Lysogene (FR0013233475 – LYS), a pioneering Phase 3…

Lysogene COVID-19 update

Find out More

Lysogene is developing therapies for children with CNS diseases.

Delivering Gene Therapy’s Promise

About Us
Our Science
Meet the Team
Diseases
Resources

Contact Us
Careers
Transparency
Compassionate Use Policy

©2020 Lysogene. All rights reserved.

Cookie Policy
Privacy Policy
Legal Notice

Get In Touch

Don’t hesitate to contact us if you need more help.

Start Typing